Loading clinical trials...
Loading clinical trials...
A Phase 1/2, Open-Label, Randomized, Dose Finding and Dose Expansion Study of Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Conditions
Interventions
Gedatolisib
Darolutamide
Locations
13
United States
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
Centre Jean Perrin
Clermont-Ferrand, France
Institut Paoli-Calmettes
Marseille, France
Centre Antoine Lacassagne
Nice, France
Institut Gustave Roussy
Villejuif, France
Hospital Clinic Barcelona
Barcelona, Spain
Start Date
January 1, 2024
Primary Completion Date
January 1, 2028
Completion Date
January 1, 2030
Last Updated
April 13, 2026
NCT07103018
NCT07451795
NCT07302763
NCT06706921
NCT02248701
NCT03677336
Lead Sponsor
Celcuity Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions